Literature DB >> 18558494

A new feasible method for fibrinogen purification based on the affinity of Staphylococcus aureus clumping factor A to fibrinogen.

Chao-Zong Liu1, Hui-Ju Cheng, Ling-Ya Chang.   

Abstract

Plasma fibrinogen participates in several physiological and pathological events thus becoming a useful studying material in biomedical research. Here we report a new convenient method for fibrinogen purification based on the affinity of Staphylococcus aureus clumping factor A to fibrinogen. Clumping factor A (ClfA) is a cell wall-anchored surface protein of S. aureus bacteria that binds with a high affinity to the fibrinogen gamma chain C-terminus via a segment encompassing the residues 221-550. This activity of ClfA (ClfA(221-550)) was produced in fusion to the C-terminus of glutathione-S-transferase (GST) with recombinant technology and used as an affinity ligand to capture plasma fibrinogen. GST-ClfA(221-550) fusion protein was immobilized onto the glutathione-conjugated beads packed in a plastic column by its GST part. Then, this affinity column was loaded with citrated and heparinized human plasma. After washing out unbound proteins, column-captured fibrinogen was specifically eluted down with a citrate buffer solution (50mM, pH 5.6). Purified human fibrinogen exhibited the ability to support platelet adhesion and aggregation and formed fibrin clot by thrombin, indicating that ClfA(221-550)-purified human fibrinogen is a functionally active product. We also found that both the rat and mouse fibrinogens could be purified as well as human fibrinogen with this method. By virtue of its simplicity and feasibility, ClfA(221-550)-based method would be very useful to the investigators who need fibrinogen to perform their studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558494     DOI: 10.1016/j.pep.2008.05.007

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  3 in total

1.  Development of Transient Recombinant Expression and Affinity Chromatography Systems for Human Fibrinogen.

Authors:  Grega Popovic; Nicholas C Kirby; Taylor C Dement; Kristine M Peterson; Caroline E Daub; Heather A Belcher; Martin Guthold; Adam R Offenbacher; Nathan E Hudson
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 6.208

Review 2.  Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.

Authors:  Fanny Risser; Ivan Urosev; Joanan López-Morales; Yang Sun; Michael A Nash
Journal:  Biophys Rev       Date:  2022-04-06

3.  Plasminogen activation triggers transthyretin amyloidogenesis in vitro.

Authors:  P Patrizia Mangione; Guglielmo Verona; Alessandra Corazza; Julien Marcoux; Diana Canetti; Sofia Giorgetti; Sara Raimondi; Monica Stoppini; Marilena Esposito; Annalisa Relini; Claudio Canale; Maurizia Valli; Loredana Marchese; Giulia Faravelli; Laura Obici; Philip N Hawkins; Graham W Taylor; Julian D Gillmore; Mark B Pepys; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2018-07-17       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.